Participants 79 117 6
patients with type 2 diabetes mellitus
Participants 231 260 6
patients with type 2 diabetes
Participants 280 419 8
multicentre, randomized, double-blind, placebo-controlled, 4-week study in patients with type 2 diabetes with suboptimal metabolic control.
Participants 420 504 6
Patients with a baseline haemoglobin A(1c) (HbA(1c)) of 7.3 to 11.0% were randomized
Participants 1712 1900 4
Addition of the DPP4 inhibitor PHX1149 to a stable regimen of metformin or metformin plus a glitazone in patients with type 2 diabetes was well tolerated and improved blood glucose control
